Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus

Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus

Erenumab is the first human monoclonal antibody to be approved as a selective therapy for migraine prophylaxis in adults. This study assessed, in a real-world setting, the efficacy of erenumab and its impact on the quality of life (QoL) of Cypriot migraine patients who had failed several treatments...

Full description

Bibliographic Details
Main Authors: Andria Tziakouri, Haritini Tsangari, Costas Michaelides
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Neurology
Subjects:
erenumab
chronic migraine
quality of life
MSQ V2.1
Cyprus
treatment failure
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.687697/full

Similar Items

Similar Items